CONFLICT OF INTEREST STATEMENT All authors declare that they have no relevant financial interests. Supporting Information Filename Description eci70080-sup-0001-FiguresS1-S2.pdfPDF document, 468.1 KB Figures S1–S2. REFERENCES 1, , , et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117-2128. 2, , , et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644-657. 3, , , et al.